This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Durect Says Pain Patch Met Goals In Clinical Study

CUPERTINO, Calif. (AP) ¿ Durect Corp. said Monday its chronic pain patch Transdur Sufentanil met all of its goals in a midstage clinical trial.

The main goal of the trial was to find the lowest dose of Sufentanil that would allow patients to transition to the drug. Secondary goals were determining the patch's safety and effectiveness, and comparing pain relief with Transdur Sufentanil to pain relief from older drugs.

Durect said patients who used the pain patch over a period of four weeks reported a decrease in pain. The company said the results show patients can be switched to Transdur Sufentanil from oral opioids like OxyContin, and fentanyl patches like Duragesic, while experiencing reduced pain.

The patch is intended to last one week. Durect said the average pain score for patients on the patch was 3.88 out of 10. That compares with a "baseline" score of 4.78.

One of the 36 patients dropped out of the trial because the patch was not working,

Endo Pharmaceuticals Holdings Corp. was developing Transdur Sufentanil, but after examining results from the trial and meeting with the Food and Drug Administration last month, it concluded Transdur Sufentanil did not fit into its long-term plans. Durect will regain rights to the patch in the U.S. and Canada on Aug. 26.

In afternoon trading, Durect shares were up 1 cent at $2.05.
Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
DRRX $1.40 -4.80%
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.02 -2.10%
TSLA $247.54 -1.60%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs